Bristol-Myers Squibb
Introduction of Robert J Lefkowitz
... Lefkowitz Gairdner Foundation International Award American Heart Association Basic Research Prize Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research Jess[r] ...
10
An update on the use of Atripla<sup>®</sup> in the treatment of HIV in the United States
... Inc, Bristol- Myers Squibb, and Merck Pharmaceuticals (the manufacturers of Atripla and its constituent medications), but these entities had no influence on this manuscript and the authors assume ...
6
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
... Bristol-Myers Squibb, Eli Lilly, Ono Pharmaceutical, Kyowa Hakko Kirin, Boehringer Ingelheim and Merck ...Kirin, Bristol-Myers Squibb, AstraZeneca, Pfizer, Chugai Pharmaceutical, ...
8
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
... Yamamoto is a consultant/advisory board member for Eisai, Takeda, and OncoTherapy Science; and reports receiving speakers bureau honoraria from AstraZeneca, Bristol-Myers Squibb Japan, [r] ...
26
Platinum Group Metal Compounds in Cancer Chemotherapy52-59
... Following the success of their collaboration on carboplatin, Johnson Matthey, ICR and Bristol-Myers Squibb (following their merger) reviewed their options for further developments in this field. Two ...
8
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
... The first use of daclatasvir in Europe outside clinical trials was via Bristol-Myers Squibb’s (BMS) early access pro- grammes. The NPP was one of these programmes. Patients were eligible to participate in ...
8
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
... Expenses: Bristol-Myers Squibb, ...Dohme, Bristol-Myers Squibb, Novartis, Amgen, GlaxoSmithKline, NeraCare GmbH, Pierre Fabre, Speakers’ Bureau: Merck Sharp & Dohme, ...
10
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
... Research Funding: Bayer (Inst), Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Medivation (Inst), Takeda (Inst), Novartis (Inst), P fi zer (Inst), BN ImmunoTherapeutics (Inst), Exel[r] ...
12
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double blind clinical trial
... by the Instituto de Salud Carlos III through a ‘ Juan Rodés ’ research fellowship (JR14/00011) and has received lecture honoraria from Pfizer, Glaxo-Smith-Kine and Lundbeck. JMM1 has received grants and served as ...
13
Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital
... Dubois, Free University of Brussels, Belgium Reviewed by: Bryan Martin Bennett, Bristol-Myers Squibb, United Kingdom Mihajlo Michael Jakovljevic, University of Kragujevac, Serbia *Corres[r] ...
14
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
... Klein reports receiving consulting fees from GlaxoSmithKline, Abbott, Pfizer, and Merck, lecture fees from Abbott, Gilead, Tibotec, Bristol-Myers Squibb, and GlaxoSmithKline and research[r] ...
6
Differential activation of the influenza virus polymerase via template RNA binding.
... 7 Differential Activation of the Influenza Virus Polymerase via Template RNA Binding CHRISTOPHER CIANCI, LAURENCE TILEY, AND MARK KRYSTAL* Department of Virology, Bristol-Myers Squibb Ph[r] ...
5
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
... Expenses: Bristol-Myers Squibb, ...Dohme, Bristol-Myers Squibb, Novartis, Amgen, GlaxoSmithKline, NeraCare GmbH, Pierre Fabre, Speakers’ Bureau: Merck Sharp & Dohme, ...
11
The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil
... AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche; ABVS: Has received supporting for international medical events from AbbVie and Jans- sen; CPA: Has ...
8
First line nivolumab plus ipilimumab in advanced non small cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
... of Bristol-Myers Squibb for their contributions as protocol managers of this study; Foundation Medicine for collaborative development of the FoundationOne CDx tumor gene pro fi ling assay; and the ...
17
Banksy: The Bristol legacy
... Performing stunts and living in the public eye are poor substitutes for lasting accomplishment. David Lee argues that being an eyecatching entertainer, who is not really that serious about either dissent or art, is only ...
5
The Roadmap to the Electronic Voting System Development: A Literature Review
... H. Myers of Rochester, New York patents the first mechanical lever voting machine, called the Myers Automatic Booth, prevents over votes, speeds up the vote counting process, and significantly reduces the ...
6
Anaesthesia in patients with renal failure
... Patient groups include those with chronic renal failure, patients with acute renal failure, and also patients with normal preoperative renal function but who have a high risk of deve[r] ...
7
Bristol and Bath by Design; To understand the economic and cultural value of design in the Bristol and Bath region
... Craneworks, Bath, a proposed interdisciplinary space for arts, science and technology has been envisioned by a team comprising figures from the city’s leading design companies, universities, entrepreneurs and other ...
96
The Myers Briggs Type Indicator (MBTI) and Promotion at Work
... (MBTI: Myers & Mc Caulley, 1985). The Myers-Briggs indicator is a Jungian-based inventory that uses a pa- per-and-pencil self-report ...The Myers-Briggs Type Indicator has been the focus of ...
6